MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Viking Therapeutics Inc

Abrir

SetorSaúde

24.59 -4.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

24.3

Máximo

25.87

Indicadores-chave

By Trading Economics

Rendimento

-10M

-35M

EPS

-0.32

Funcionários

36

EBITDA

-9.6M

-46M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+248.66% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-570M

2.7B

Abertura anterior

29.24

Fecho anterior

24.59

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Viking Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de abr. de 2025, 14:14 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7 de fev. de 2025, 10:30 UTC

Principais Notícias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 de dez. de 2024, 15:04 UTC

Principais Notícias

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 de dez. de 2024, 14:53 UTC

Principais Notícias

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 de nov. de 2024, 12:22 UTC

Principais Notícias

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 de nov. de 2024, 12:00 UTC

Principais Notícias

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 de nov. de 2024, 10:11 UTC

Ações em Alta

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 de out. de 2024, 12:01 UTC

Principais Notícias

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 de out. de 2024, 12:01 UTC

Principais Notícias

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 de set. de 2024, 13:55 UTC

Principais Notícias

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 de jul. de 2024, 15:03 UTC

Ganhos

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Comparação entre Pares

Variação de preço

Viking Therapeutics Inc Previsão

Preço-alvo

By TipRanks

248.66% parte superior

Previsão para 12 meses

Média 89.92 USD  248.66%

Máximo 125 USD

Mínimo 30 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Viking Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

17 ratings

15

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

25.48 / 25.7Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.